MCID: HYP017
MIFTS: 45

Hypophosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hypophosphatemia

MalaCards integrated aliases for Hypophosphatemia:

Name: Hypophosphatemia 12 28 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050336
UMLS 69 C0085682

Summaries for Hypophosphatemia

MalaCards based summary : Hypophosphatemia is related to hereditary hypophosphatemic rickets and hypophosphatemic rickets, autosomal dominant. An important gene associated with Hypophosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are FGF signaling pathway and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs Iron and Micronutrients have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Hypophosphatemia

Diseases related to Hypophosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 hereditary hypophosphatemic rickets 32.9 SLC34A1 SLC34A3
2 hypophosphatemic rickets, autosomal dominant 32.6 FGF23 PHEX SFRP4 SLC34A3
3 dent disease 1 31.4 CLCN5 SLC34A3
4 metaphyseal chondrodysplasia, jansen type 31.4 FGF23 PTH
5 autosomal recessive hypophosphatemic rickets 31.2 DMP1 ENPP1 FGF23 PHEX
6 hypophosphatemic rickets, x-linked dominant 31.2 DMP1 FGF23 PHEX PTH SFRP4 SLC34A1
7 oncogenic osteomalacia 31.1 DMP1 FGF23 PHEX PTH SFRP4
8 enthesopathy 30.3 DMP1 FGF23 PHEX
9 hypercalciuria, absorptive, 2 30.2 CLCN5 SLC34A3
10 cohen-gibson syndrome 30.0 BGLAP FGF23
11 nephrolithiasis 30.0 CLCN5 SLC34A1 SLC34A3
12 hyperphosphatemia 29.8 FGF23 PTH SLC34A1
13 mccune-albright syndrome 29.8 BGLAP FGF23
14 nephrolithiasis, calcium oxalate 29.7 CLCN5 SLC34A1
15 arterial calcification of infancy 29.6 ENPP1 FGF23 PHEX
16 fibrous dysplasia 29.5 BGLAP FGF23
17 fanconi syndrome 29.5 CLCN5 PTH SLC34A1
18 osteomalacia 29.5 BGLAP DMP1 FGF23 PHEX SFRP4
19 hypophosphatemic rickets with hypercalciuria, hereditary 29.5 DMP1 ENPP1 FGF23 PHEX PTH SFRP4
20 raine syndrome 29.5 DMP1 FAM20C FGF23
21 hyperparathyroidism 29.4 BGLAP FGF23 PHEX PTH
22 hypophosphatemic rickets, x-linked recessive 29.4 CLCN5 DMP1 DSPP ENPP1 FGF23 PHEX
23 secondary hyperparathyroidism of renal origin 29.2 BGLAP FGF23 PTH
24 hypoparathyroidism 29.2 BGLAP FGF23 PTH
25 primary hyperparathyroidism 29.2 BGLAP FGF23 PTH
26 hypophosphatasia 29.0 DSPP ENPP1 PHEX
27 osteoporosis 29.0 BGLAP FGF23 PTH SLC34A1
28 rickets 27.9 BGLAP CLCN5 DMP1 ENPP1 FGF23 PHEX
29 cutaneous-skeletal hypophosphatemia syndrome 12.2
30 hypophosphatemia, renal, with intracerebral calcifications 11.9
31 dominant hypophosphatemia with nephrolithiasis or osteoporosis 11.9
32 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.6
33 hypophosphatemic rickets, autosomal recessive, 1 11.6
34 hypophosphatemic rickets, autosomal recessive, 2 11.4
35 panostotic fibrous dysplasia 11.2
36 thyrotoxic periodic paralysis 11.1
37 vitamin d hydroxylation-deficient rickets, type 1a 10.9
38 exostoses, multiple, type i 10.8
39 fanconi renotubular syndrome 1 10.8
40 tumoral calcinosis, hyperphosphatemic, familial 10.8
41 lowe oculocerebrorenal syndrome 10.8
42 nephrolithiasis/osteoporosis, hypophosphatemic, 2 10.8
43 opsismodysplasia 10.5 FGF23 PHEX
44 familial tumoral calcinosis 10.4 FGF23 PHEX
45 hypervitaminosis d 10.2 FGF23 PTH
46 ossification of the posterior longitudinal ligament of spine 10.2 BGLAP ENPP1
47 calciphylaxis 10.2 FGF23 PTH
48 calcinosis 10.2 ENPP1 FGF23 PHEX
49 hepatitis 10.2
50 aminoaciduria 10.2 CLCN5 SLC34A1

Graphical network of the top 20 diseases related to Hypophosphatemia:



Diseases related to Hypophosphatemia

Symptoms & Phenotypes for Hypophosphatemia

MGI Mouse Phenotypes related to Hypophosphatemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 SLC34A3 FGF23 PHEX CLCN5 PTH DMP1
2 homeostasis/metabolism MP:0005376 9.96 FAM20C SLC34A3 FGF23 PHEX CLCN5 PTH
3 craniofacial MP:0005382 9.77 FAM20C PHEX CLCN5 PTH DMP1
4 limbs/digits/tail MP:0005371 9.63 FAM20C FGF23 PHEX PTH DMP1 SFRP4
5 renal/urinary system MP:0005367 9.61 FGF23 PHEX CLCN5 DMP1 SFRP4 ENPP1
6 skeleton MP:0005390 9.32 SLC34A3 FGF23 PHEX CLCN5 PTH DMP1

Drugs & Therapeutics for Hypophosphatemia

Drugs for Hypophosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7439-89-6 23925
2 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3 Pharmaceutical Solutions Phase 4,Phase 2
4 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Ferric Compounds Phase 4,Phase 3,Phase 2
6 Hematinics Phase 4,Phase 3,Phase 2
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
8
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
9 Hormone Antagonists Phase 3,Phase 1,Phase 2
10 Hormones Phase 3,Phase 1,Phase 2
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
12 Vitamins Phase 3,Phase 1
13 Calcimimetic Agents Phase 3,Phase 1
14 Cinacalcet Hydrochloride Phase 3,Phase 1
15 Bone Density Conservation Agents Phase 3,Phase 1,Early Phase 1
16 Ergocalciferols Phase 3
17 Calcium, Dietary Phase 3,Phase 1,Phase 2,Early Phase 1
18 Mitogens Phase 3,Phase 2,Phase 1
19 Antibodies Phase 3,Phase 2
20 Antibodies, Monoclonal Phase 3,Phase 2
21 Immunoglobulins Phase 3,Phase 2
22 Calciferol Nutraceutical Phase 3
23 Vitamin D2 Nutraceutical Phase 3
24
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
25
Lenalidomide Approved Phase 2 191732-72-6 216326
26 Cariostatic Agents Phase 2
27 potassium phosphate Phase 2,Phase 1
28 Protective Agents Phase 2
29 Anticoagulants Phase 2
30 Blood Substitutes Phase 2
31 Dextrans Phase 2
32 Iron-Dextran Complex Phase 2
33 Plasma Substitutes Phase 2
34 Anti-HIV Agents Phase 2
35 Anti-Infective Agents Phase 2
36 Anti-Retroviral Agents Phase 2
37 Antiviral Agents Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 2
39 Reverse Transcriptase Inhibitors Phase 2
40
Tenofovir Phase 2 147127-20-6 464205
41 Angiogenesis Inhibitors Phase 2
42 Angiogenesis Modulating Agents Phase 2
43 Anti-Bacterial Agents Phase 2
44 Immunosuppressive Agents Phase 2
45 Phosphorus Supplement Nutraceutical Phase 1, Phase 2
46
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
47
Denosumab Approved Phase 1 615258-40-7
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
49
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
50
Nicotinamide Approved, Investigational, Nutraceutical Phase 1 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 51)

# Name Status NCT ID Phase Drugs
1 The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer Unknown status NCT01845922 Phase 4
2 A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer Recruiting NCT02905539 Phase 4 Iron Isomaltoside 1000;Ferric Carboxymaltose
3 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Completed NCT00417612 Phase 3 Paricalcitol
4 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
5 Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets Completed NCT01237288 Phase 3 Z-521
6 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05) Recruiting NCT03237065 Phase 3 Iron Isomaltoside (Monofer);Ferric carboxymaltose
7 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04) Recruiting NCT03238911 Phase 3 Iron isomaltoside (Monofer);Ferric carboxymaltose
8 Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis Recruiting NCT03346369 Phase 3 Lanthanum Carbonate
9 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02526160 Phase 3
10 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02537431 Phase 3
11 Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) Active, not recruiting NCT02915705 Phase 3 Oral Phosphate;Active Vitamin D
12 A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia Active, not recruiting NCT03233126 Phase 3 KRN23
13 Investigating a New Way of Giving Medicine to Newborn and Preterm Babies Unknown status NCT01676844 Phase 2 Oral thin film therapy (Potassium acid phosphate oral thin films);Standard therapy (Potassium acid phosphate oral solution)
14 An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia Completed NCT01571596 Phase 1, Phase 2 KRN23
15 A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia Completed NCT01340482 Phase 1, Phase 2 KRN23
16 Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding Completed NCT01307007 Phase 2 Ferric Carboxymaltose (FCM);Iron Dextran Injection
17 Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men Completed NCT00131677 Phase 2 tenofovir disoproxil fumarate;placebo
18 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
19 Growth Hormone Treatment in Children With Hypophosphatemic Rickets Completed NCT02720770 Phase 1, Phase 2 norditropine simplex
20 Role Of Phosphorus And FGF 23 In Patients With Dent Disease Recruiting NCT02016235 Phase 1, Phase 2 Phosphorus Supplement
21 Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against FGF23, in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02163577 Phase 2 KRN23
22 Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02750618 Phase 2 KRN23
23 Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) Active, not recruiting NCT02312687 Phase 2 KRN23
24 Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets Unknown status NCT00473187 Phase 1 somatropin
25 Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets Unknown status NCT00195936 Phase 1 Cinacalcet
26 A Study of KRN23 in X-linked Hypophosphatemia Completed NCT00830674 Phase 1 Placebo;KRN23
27 Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis Completed NCT01464931 Phase 1 Denosumab
28 A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia Completed NCT02181764 Phase 1 KRN23
29 Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. Terminated NCT00622479 Phase 1 Sorafenib (Nexavar, BAY43-9006)
30 Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Terminated NCT01748812 Phase 1 Osteomalacia
31 Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant Unknown status NCT01011114 Cinacalcet;Placebo
32 Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) Unknown status NCT01230697 Sorafenib
33 Calcimimetics in Hypophosphatemic Rickets Unknown status NCT00844740 Cinacalcet
34 Calcitonin for Treating X-linked Hypophosphatemia Completed NCT01652573 nasal salmon calcitonin;Saline Nasal Spray Placebo
35 FGF-23 Suppressibility by Calcitonin Completed NCT00688077 Calcitonin;Placebo
36 Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels? Completed NCT02420119
37 A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients Completed NCT01163669
38 Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism Completed NCT03027349
39 Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4 Completed NCT00764816
40 Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion. Completed NCT01991574 Early Phase 1 Calcium acetate;Placebo
41 Leptin, IGF1 and the Refeeding Index Completed NCT01227850
42 Studying Phosphorus Metabolism Completed NCT00066183
43 Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Completed NCT00099762
44 Milk Products in the Treatment of Hypophosphatemic Rickets Completed NCT03348644
45 Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients Completed NCT01578824
46 Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Recruiting NCT01660308
47 Refeeding Syndrome Among Older Adults Recruiting NCT03141489
48 Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Recruiting NCT02233322
49 Hypophosphatemic Rickets in Norway Active, not recruiting NCT01057186 Sevelamer
50 Registry for Patients With X-linked Hypophosphatemia Not yet recruiting NCT03193476

Search NIH Clinical Center for Hypophosphatemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Hypophosphatemia

Genetic tests related to Hypophosphatemia:

# Genetic test Affiliating Genes
1 Hypophosphatemia 28

Anatomical Context for Hypophosphatemia

MalaCards organs/tissues related to Hypophosphatemia:

38
Kidney, Bone, Liver, Skeletal Muscle, Prostate, Myeloid, Breast

Publications for Hypophosphatemia

Articles related to Hypophosphatemia:

(show top 50) (show all 630)
# Title Authors Year
1
Association Between Iron-Deficiency Anemia and Hypophosphatemia. ( 29031590 )
2018
2
Reply: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29314243 )
2018
3
X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases -Prospect for new treatment. ( 29381780 )
2018
4
Prevention of hypophosphatemia during continuous renal replacement therapy-An overlooked problem. ( 29405468 )
2018
5
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. ( 29383408 )
2018
6
Specific ablation of mouse Fam20C in cells expressing type I collagen leads to skeletal defects and hypophosphatemia. ( 28620244 )
2017
7
Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. ( 28805320 )
2017
8
Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29068481 )
2017
9
Hypophosphatemia associated risk factors in pediatric intensive care patients. ( 29168361 )
2017
10
Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures. ( 28880715 )
2017
11
Dental management of patients with X-linked hypophosphatemia. ( 28503481 )
2017
12
Post-Transplant Hypophosphatemia and the Risk of Death-Censored Graft Failure and Mortality after Kidney Transplantation. ( 28546442 )
2017
13
Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase. ( 28690207 )
2017
14
Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. ( 27884786 )
2017
15
Serum calcitriol levels in a patient with X-linked hypophosphatemia complicated by autosomal dominant polycystic kidney disease. ( 28509123 )
2017
16
Correction to: X-linked hypophosphatemia and growth. ( 29110236 )
2017
17
Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. ( 28728941 )
2017
18
Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study. ( 29143140 )
2017
19
Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers. ( 29126251 )
2017
20
Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer. ( 28462158 )
2017
21
Hypophosphatemia in Users of Cannabis. ( 27692442 )
2017
22
Craniofacial and dental characteristics of patients with vitamin-D-dependent rickets type 1A compared to controls and patients with X-linked hypophosphatemia. ( 28608052 )
2017
23
Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29281128 )
2017
24
X-linked hypophosphatemia with enthesopathy. ( 28784895 )
2017
25
Euglycemic Diabetic Ketoacidosis Accompanied by Severe Hypophosphatemia During Recovery in a Patient With Type 2 Diabetes Being Treated With Canagliflozin/Metformin Combination Therapy. ( 29109617 )
2017
26
Risk Factors for the Development of Refeeding Syndrome-Like Hypophosphatemia in Very Low Birth Weight Infants. ( 29104345 )
2017
27
Tumour genesis syndrome: severe hypophosphatemia and hypokalemia may be ominous presenting findings in childhood acute myeloid leukaemia. ( 28474100 )
2017
28
Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia. ( 28764922 )
2017
29
Corn-Soy-Blend Fortified with Phosphorus to Prevent Refeeding Hypophosphatemia in Undernourished Piglets. ( 28081252 )
2017
30
Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia. ( 29083055 )
2017
31
Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events. ( 28616212 )
2017
32
Hypophosphatemia after nontraumatic intracranial hemorrhage. ( 28497591 )
2017
33
Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. ( 28600887 )
2017
34
[Identification of a novel splicing mutation of PHEX gene in a pedigree affected with X-linked hypophosphatemia]. ( 28397222 )
2017
35
Aggressive Treatment of Life-Threatening Hypophosphatemia During Recovery From Fulminant Hepatic Failure: A Case Report. ( 29088996 )
2017
36
Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients. ( 28079295 )
2017
37
The influence of hypophosphatemia on outcomes of low- and high-intensity continuous renal replacement therapy in critically ill patients with acute kidney injury. ( 28904875 )
2017
38
Cardiovascular consequences of hypophosphatemia. ( 28497938 )
2017
39
Preventing/treating hypophosphatemia by adding phosphate to the dialysate. ( 26689145 )
2016
40
Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. ( 27859495 )
2016
41
Hypophosphatemia in Enterally Fed Patients in the Surgical Intensive Care Unit: Common but Unrelated to Timing of Initiation or Aggressiveness of Nutrition Delivery. ( 27562444 )
2016
42
Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum. ( 27994603 )
2016
43
FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice. ( 26762209 )
2016
44
Hypophosphatemia, Hypomagnesemia, and Hypokalemia in Pediatric Patients Before and During Exclusive Individualized Parenteral Nutrition. ( 26869613 )
2016
45
Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. ( 27497815 )
2016
46
Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia. ( 27679714 )
2016
47
Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia. ( 27821544 )
2016
48
Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia. ( 26792657 )
2016
49
A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib. ( 27194982 )
2016
50
Targeting the ligand in hypophosphatemia. ( 27885013 )
2016

Variations for Hypophosphatemia

Expression for Hypophosphatemia

Search GEO for disease gene expression data for Hypophosphatemia.

Pathways for Hypophosphatemia

Pathways related to Hypophosphatemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.93 BGLAP FGF23
2 10.81 BGLAP PTH
3 10.55 BGLAP PTH
4 9.95 BGLAP FGF23 PTH

GO Terms for Hypophosphatemia

Cellular components related to Hypophosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 BGLAP ENPP1 FAM20C FGF23 PTH SFRP4
2 vesicle GO:0031982 9.33 BGLAP SLC34A1 SLC34A3
3 endoplasmic reticulum lumen GO:0005788 9.26 BGLAP DMP1 FAM20C FGF23
4 extracellular region GO:0005576 9.23 BGLAP DMP1 DSPP ENPP1 FAM20C FGF23

Biological processes related to Hypophosphatemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 DMP1 FAM20C FGF23 SLC34A1
2 ossification GO:0001503 9.71 BGLAP DMP1 DSPP SLC34A1
3 skeletal system development GO:0001501 9.65 BGLAP DSPP FAM20C PHEX PTH
4 regulation of bone mineralization GO:0030500 9.63 BGLAP ENPP1 FGF23
5 ATP metabolic process GO:0046034 9.62 ENPP1 FAM20C
6 bone mineralization GO:0030282 9.61 BGLAP PHEX
7 positive regulation of bone mineralization GO:0030501 9.61 FAM20C PTH
8 response to vitamin D GO:0033280 9.61 BGLAP PHEX PTH
9 response to cadmium ion GO:0046686 9.6 PTH SLC34A1
10 phosphate-containing compound metabolic process GO:0006796 9.59 ENPP1 FGF23
11 phosphate ion transmembrane transport GO:0035435 9.58 SLC34A1 SLC34A3
12 response to lead ion GO:0010288 9.58 PTH SLC34A1
13 response to magnesium ion GO:0032026 9.57 FGF23 SLC34A1
14 response to growth hormone GO:0060416 9.56 PHEX SLC34A1
15 phosphate ion transport GO:0006817 9.55 SLC34A1 SLC34A3
16 sodium-dependent phosphate transport GO:0044341 9.54 SLC34A1 SLC34A3
17 cellular response to vitamin D GO:0071305 9.54 BGLAP FGF23 PHEX
18 response to parathyroid hormone GO:0071107 9.51 PTH SLC34A1
19 cellular response to parathyroid hormone stimulus GO:0071374 9.5 FGF23 PHEX SLC34A1
20 dentinogenesis GO:0097187 9.49 FAM20C SLC34A1
21 response to sodium phosphate GO:1904383 9.48 FGF23 PHEX
22 phosphate ion homeostasis GO:0055062 9.33 FGF23 SFRP4 SLC34A1
23 cellular phosphate ion homeostasis GO:0030643 9.26 ENPP1 FGF23 SLC34A1 SLC34A3
24 biomineral tissue development GO:0031214 9.1 BGLAP DMP1 DSPP ENPP1 FAM20C PHEX

Molecular functions related to Hypophosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.55 BGLAP DMP1 DSPP ENPP1 FAM20C
2 sodium:phosphate symporter activity GO:0005436 8.96 SLC34A1 SLC34A3
3 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.62 SLC34A1 SLC34A3

Sources for Hypophosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....